Roche's Genentech Gets FDA sBLA Acceptance for Lunsumio VELO And Polivy Combination In Relapsed or Refractory Large B-Cell Lymphoma

– Filing acceptance based on data from the Phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk of disease progression or death –

– People with relapsed or refractory LBCL represent one of the highest unmet need populations in lymphoma and require timely access to effective therapies –

– If approved, this outpatient-ready regimen could enable access to care in the community setting, where most U.S. patients receive treatment –